相似文献
1
Compassionate use of experimental therapies: who should decide?
EMBO Mol Med. 2015 Oct;7(10):1248-50. doi: 10.15252/emmm.201505262.
2
Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
J Law Med Ethics. 2010 Summer;38(2):277-85. doi: 10.1111/j.1748-720X.2010.00488.x.
3
[A comprehensive assessment of ATMP. Difficulties and approaches].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jul;54(7):843-8. doi: 10.1007/s00103-011-1300-7.
4
Unproven stem cell therapies: is it my right to try?
Ann Ist Super Sanita. 2019 Apr-Jun;55(2):179-185. doi: 10.4415/ANN_19_02_10.
5
Right-to-Try Investigational Therapies for Incurable Disorders.
Continuum (Minneap Minn). 2017 Oct;23(5, Peripheral Nerve and Motor Neuron Disorders):1451-1457. doi: 10.1212/CON.0000000000000515.
6
Stem-cell ruling riles researchers.
Nature. 2013 Mar 28;495(7442):418-9. doi: 10.1038/495418a.
7
The social production of evidence: regenerative medicine and the 21st Century Cures Act.
Regen Med. 2017 Sep;12(6):581-586. doi: 10.2217/rme-2017-0058. Epub 2017 Oct 4.
8
Comments on ethics of experimental therapies.
Fetal Diagn Ther. 2004 Mar-Apr;19(2):111-2. doi: 10.1159/000075131.
9
Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
Am J Bioeth. 2017 Oct;17(10):70-71. doi: 10.1080/15265161.2017.1365196.
10
FDA's claims over stem cells upheld.
Nature. 2012 Aug 2;488(7409):14. doi: 10.1038/488014a.
引用本文的文献
1
Stem cells, cell therapies, and bioengineering in lung biology and disease 2021.
Am J Physiol Lung Cell Mol Physiol. 2022 Sep 1;323(3):L341-L354. doi: 10.1152/ajplung.00113.2022. Epub 2022 Jun 28.
2
Current regulatory approaches for accessing potential COVID-19 therapies.
J Pharm Policy Pract. 2020 May 16;13:16. doi: 10.1186/s40545-020-00222-6. eCollection 2020.
3
Advanced therapies push regulatory boundaries: Novel therapeutic approaches require more regulatory flexibility and transparency.
EMBO Rep. 2017 Dec;18(12):2101-2104. doi: 10.15252/embr.201745345. Epub 2017 Nov 9.
4
Characterizing expanded access and compassionate use programs for experimental drugs.
BMC Res Notes. 2017 Jul 28;10(1):350. doi: 10.1186/s13104-017-2687-5.
5
An analysis of common ethical justifications for compassionate use programs for experimental drugs.
BMC Med Ethics. 2016 Oct 18;17(1):60. doi: 10.1186/s12910-016-0145-x.
本文引用的文献
1
Stem cell hype: media portrayal of therapy translation.
Sci Transl Med. 2015 Mar 11;7(278):278ps4. doi: 10.1126/scitranslmed.3010496.
2
The European Court of Human Rights' ruling on unproven stem cell therapies: a missed opportunity?
Stem Cells Dev. 2014 Dec;23 Suppl 1(Suppl 1):39-43. doi: 10.1089/scd.2014.0361.
3
Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use.
Ann Intern Med. 2015 Jan 20;162(2):141-2. doi: 10.7326/M14-2002.
4
The strange allure of state "right-to-try" laws.
JAMA Intern Med. 2014 Dec;174(12):1885-6. doi: 10.1001/jamainternmed.2014.5767.
5
Stem cells: taking a stand against pseudoscience.
Nature. 2014 Jun 19;510(7505):333-5. doi: 10.1038/510333a.
6
Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries.
Trials. 2010 Nov 12;11:104. doi: 10.1186/1745-6215-11-104.
7
From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy.
Yale J Health Policy Law Ethics. 2010 Winter;10(1):135-96.
8
The whys of cancer quackery.
Cancer. 1984 Feb 1;53(3 Suppl):815-9. doi: 10.1002/1097-0142(19840201)53:3+<815::aid-cncr2820531334>3.0.co;2-u.
Zotero 插件